Blog
RSS Feed- All categories
- United States (FDA)
-
All tags
- 3D printing
- Academia
- Accelerated approval
- Accelerated review
- Advertising
- Affordability
- Ageing
- Agenda
- Alzheimer's disease
- Application
- Artificial intelligence
- Asthma
- Australia
- Bias
- Biomarker
- Biomedical research
- Biosimilar
- Blood product
- Breakthrough therapy designation
- Breast cancer
- Budget
- Budget impact analysis
- California
- Canada
- Cancer
- Cardiovascular disease
- Cellular therapy
- Children
- China
- Chronic obstructive pulmonary disease
- Clinical trial
- Co-dependent technology
- Collaboration
- Combination product
- Committee
- Communication
- Comparison
- Compassionate use
- Consultation
- Continuing education
- Cost analysis
- Costs
- COVID-19
- Data
- Database
- Decision making
- Development
- Device
- Diabetes mellitus
- Diagnosis
- Diagnostic agent
- Digital health
- Direct to consumer advertising
- Disease
- Dossier
- Drug development
- Drug device combination
- Drug resistance
- Drug utilisation
- EMA
- Engagement
- England
- Equity
- Europe
- Expenditure
- Expert opinion
- Fast track
- FDA
- Fees and charges
- Framework
- Free trade agreement
- Funding
- Gender
- Gene therapy
- Generic medicine
- Geriatrics
- Global
- Guidelines
- Health care system
- Health plans
- Health policy
- Health related quality of life
- Health technology assessment
- Hepatitis C
- HIV infection
- Importation
- India
- Influenza
- Innovation
- Intellectual property
- Investment
- Japan
- Launch
- Management
- Market access
- Massachussetts
- Medicaid
- Medicare
- Medicinal preparation
- Medicine
- Membership
- Merger & acquisition
- Meta-analysis
- Modelling & simulation
- Multiple sclerosis
- New Zealand
- Nomenclature
- Oncology
- Orphan drug
- Outcome
- Over the counter
- Paediatrics
- Pain
- Patent protection
- Patient
- Patient copayment
- Patient reported outcome
- Performance indicators
- Pharmaceutical industry
- Pharmacy
- Placebo
- Post-market review
- Prevention
- Pricing
- Priority review
- Procedure
- Process
- Public health
- Publication
- Randomisation
- Real world evidence
- Regenerative medicine
- Registration
- Regulation
- Reimbursement
- Remuneration
- Report
- Research
- Return on investment
- Revenue
- Review
- Risk management
- Risk sharing agreement
- Russia
- Safety
- Scientific advice
- Singapore
- Social media
- Software
- South Korea
- Standards
- Statistics
- Submission
- Supply
- Surrogate outcome
- Survey
- Switzerland
- Systematic review
- Targeted therapy
- Timelines
- Transparency
- Type 2 diabetes mellitus
- US
- Vaccine
- Validation
- Value
- Website
- Withdrawal
- Workshop
Posted by Michael Wonder on 08 May 2019
A $2 million drug is about to hit the market
8 May 2019 -Insurers, drug makers grapple with new payment models for gene therapies that can cure diseases in one ...
Posted by Michael Wonder on 20 Sep 2018
Generics would hit the market faster under Senate bill, saving more than 3 billion dollars, says CBO
19 September 2018 - Lower-price drugs would hit the market faster under a bipartisan bill awaiting a vote in the ...